Myriad: Keeping a low profile

“To be honest it came out of the blue: it was a complete shock,” says Ben Jackson of the lawsuit that landed on US biotech company Myriad Genetics’ doormat in May 2009. Led by the American Civil Liberties Union (ACLU), the suit claimed two of the company’s prized gene patents are invalid, unconstitutional and stifle diagnostic testing and research.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Jurisdiction reports

US - patents: 2011 federal circuit patent rulings

1 February 2012 Twenty eleven was an extremely busy year for the US ‘patent court’.

Patents

ACLU files Supreme Court brief in Myriad case

29 January 2013 The American Civil Liberties Union (ACLU) has urged the US Supreme Court to invalidate Myriad Genetics’ patent claims over two human genes linked to breast and ovarian cancer.

Patents

US Supreme Court strikes Myriad blow

13 June 2013 The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Trade secrets: Navigating the maze of definition and regulation

IBM, Verily, litigation funder on the art of leveraging patents

Number crunching: Why Optis v Apple is the UK FRAND case to watch

Trouble at the USPTO—Part II: Bracing for impact

US patent bills seek to wind back the clock—but critics aren’t happy

Trump chooses crypto-focused litigation funding expert to lead USPTO

Jury hands Lululemon partial victory against Nike in ‘Flyknit’ feud

Non-practising entity litigation at the UPC: A US perspective

Myriad: Keeping a low profile

More on this story

Editor's picks

Editor's picks

More articles